Metabolomics study on the effect of combination treatment between pioglitazone and piceatannol on non-alcoholic fatty liver disease in rats

Document Type

Presentation

Publication Date

2019

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver disorders worldwide. Under the current obesity epidemic, NAFLD prevalence increases and imposes a huge social and economic burden to our society. Given the importance of insulin resistance in the pathogenesis of NAFLD, insulin sensitizers have been broadly investigated in the treatment of NAFLD. Unfortunately, clinical studies have not demonstrated a consistent benefit in NAFLD patients treated with insulin sensitizers. Epidemiological studies have demonstrated that the consumption of foods high in phenolic compounds is associated with lower risks of many chronic diseases. Piceatannol (PIC) (Figure 1A) is a natural analog of resveratrol (Figure 1B) , a well-known dietary supplement. Although resveratrol has shown pre-clinically to have beneficial effects on various chronic diseases such as cardiovascular diseases, poor bioavailability and rapid metabolism have limited the use of resveratrol in dietary intervention to improve health and prevent chronic diseases. It has been showed that combination drug therapy utilizes more than one medication but each agent is given at a dose much lower than the normal therapeutic dose (i.e., minimal side effects are anticipated) resulting in synergistic therapeutic outcomes. In this study, we used metabolomics approaches to investigate a novel drug therapy using pioglitazone (PG, a commonly used insulin sensitizer) in combination with piceatannol, a natural analog of resveratrol, to treat NAFLD in rat fed with high fat diet (HFD).

Source Publication

15th Annual Conference of the Metabolomics Society - Metabolomics 2019, Hague

This document is currently not available here.

Share

COinS